Department of Urology, Institute of Oncology "Prof. Dr. Ion Chiricuţă", Cluj-Napoca.
Arch Ital Urol Androl. 2024 Oct 2;96(3):12643. doi: 10.4081/aiua.2024.12643.
Open inguinal lymph node dissection (OILND) plays a crucial role in penile cancer management, but in order to improve patient outcomes, minimally-invasive (MILND) approaches were developed. Our "bottoms-up" MILND is a novel endoscopic technique, changing the way the sequence of dissection is performed. This study aims to compare our approach to the current standard of OILND in terms of oncologic and perioperative outcomes.
In our database, from 2016 to 2023, 12 patients underwent OILND and 16 had a "bottoms-up" MILND, which is performed with a three port configuration, starting the dissection under the fascia lata, dissecting the femoral vessels in the most distal part of the femoral fossa, followed by dissection of the proximal and superficial lymph nodes at the top of thefemoral triangle.
For MILND, median operation time per groin was shorter (58 vs 64 minutes, p=0.34), patients presented shorter hospital stays (10 vs 18 days, p=0.32) and fewer days with drains (14 vs 24 days, p=0.01). Median lymph node yield per groin was higher for MILND (10 vs 9 nodes, p=0.7), but OILND had a higher median of positive lymph nodes (4 vs 3 nodes, p=0.63). MILND patients experienced a lower incidence of major complications (33% vs 58%, p=0.007).
We have proved that our technique of MILND is not inferior to the current standard and we believe that it can further improve patient outcomes with a safer, simplified and easily reproducible approach.
开放式腹股沟淋巴结清扫术(OILND)在阴茎癌的治疗中起着至关重要的作用,但为了改善患者的预后,微创(MILND)方法被开发出来。我们的“自下而上”MILND 是一种新的内镜技术,改变了手术解剖的顺序。本研究旨在比较我们的方法与 OILND 的当前标准在肿瘤学和围手术期结果方面的差异。
在我们的数据库中,2016 年至 2023 年期间,有 12 例患者接受了 OILND,16 例患者接受了“自下而上”的 MILND,该方法采用三端口配置,从阔筋膜下开始解剖,在股窝最远端解剖股血管,然后在股三角顶部解剖近端和浅表淋巴结。
对于 MILND,每个腹股沟手术的中位手术时间更短(58 分钟比 64 分钟,p=0.34),患者的住院时间更短(10 天比 18 天,p=0.32),引流管留置时间更短(14 天比 24 天,p=0.01)。每个腹股沟 MILND 的中位淋巴结收获量更高(10 个比 9 个,p=0.7),但 OILND 的阳性淋巴结中位数更高(4 个比 3 个,p=0.63)。MILND 患者的主要并发症发生率较低(33%比 58%,p=0.007)。
我们已经证明,我们的 MILND 技术并不逊于当前的标准,我们相信,它可以通过一种更安全、简化和易于复制的方法进一步改善患者的预后。